Хронический лимфоцитарный лейкоз/лимфома из малых лимфоцитов

1. Packham G, Stevenson F. The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia. Semin Cancer Biol 2010; 20 (6): 391–9.
2. Vardi A et al. Immunogenetic studies of chronic lymphocytic leukemia: Revelations and speculations about ontogeny and clinical evolution. Cancer Res 2014; 74 (16): 4211–6.
3. Murray F et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: Implications for the role of antigen selection in leukemogenesis. Blood 2008; 111 (3): 1524–33.
4. Strati P, Shanafelt T.D. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: Diagnosis, natural history, and risk stratification. Blood. Am Soc Hematol 2015; 126 (4): 454–62.
5. Zhang S, Kipps TJ. The Pathogenesis of Chronic Lymphocytic Leukemia. Annu Rev Pathol Mech Dis 2014; 9 (1): 103–18.
6. Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 2013; 34 (12): 592–601.
7. Morton LM et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107 (1): 265–76.
8. Watson L, Wyld P, Catovsky D. Disease burden of chronic lymphocytic leukaemia within the European Union. Eur J Haematol 2008; 81 (4): 253–8.
9. Jemal A et al. Cancer statistics, 2007. CA. Cancer J Clin 2007; 57 (1): 43–66.
10. Dores GM et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: Overview of the descriptive epidemiology. Br J Haematol 2007; 139 (5): 809–19.
11. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д.Каприна, В.В.Старинского, Г.В.Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018.
[Malignant neoplasms in Russia in 2017 (morbidity and mortality). Pod red. A.D.Kaprina, V.V.Starinskogo, G.V.Petrovoi. Moscow: MNIOI im. P.A. Gertsena – filial FGBU "NMITs radiologii" Minzdrava Rossii, 2018 (in Russian).]
12. Hallek M et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018; 131 (25): 2745–60.
13. Armitage J.O. Staging Non-Hodgkin Lymphoma. CA. Cancer J Clin. Wiley 2005; 55 (6): 368–76.
14. An international prognostic index for patients with chronic lymphocytic leukaemia ­(CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 2016; 17 (6): 779–90.
15. Swerdlow SH et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016.
16. Никитин Е.А. и др. Хронический лимфолейкоз. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 179–200.
[Nikitin E.A. et al. Khronicheskii limfoleikoz. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 179–200 (in Russian).]
17. Morice WG et al. Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: Comparative analysis of flow cytometry and tissue biopsy in 252 patients. Mayo Clin Proc 2008; 83 (7): 776–85.
18. Rawstron AC et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008; 359 (6): 575–83.
19. Molica S, Giannarelli D, Montserrat E. Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis. Clin Lymphoma Myeloma Leuk 2019; 19 (7): 423–30.
20. Rossi D et al. Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naïve patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50 (4): 604–11.
21. Conte MJ et al. Use of positron emission tomography- computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma Informa Healthcare 2014; 55 (9): 2079–84.
22. Parikh SA, Kay NE, Shanafelt TD. How we treat Richter syndrome. Blood 2014; 123 (11): 1647–57.
23. Hallek M et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010; 376 (9747): 1164–74.
24. Fischer K et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial. Blood 2016; 127 (2): 208–15.
25. Fischer K et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012; 30 (26): 3209–16.
26. Eichhorst B et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2016; 17 (7): 928–42.
27. Shanafelt T, Wang V, Kay N. A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): a trial of the ECOG-ACRIN Cancer. ASH Annual Meeting. 2018. P. LBA-4.
28. Burger JA et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 2019; 133 (10): 1011–9.
29. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology. Chronic Lymphocytic Leukemia. Small Lymphocytic Lymphoma. 2019.
30. Assouline S et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia ­(SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematol 2016; 3 (3): e128–38.
31. Goede V et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370 (12): 1101–10.
32. Michallet AS et al. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: Primary analysis of the randomized, open-label mable study. Haematologica. Ferrata Storti Foundation 2018; 103 (4): 698–706.
33. Burger JA et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015; 373 (25): 2425–37.
34. Burger JA et al. Ibrutinib for First-Line Treatment of Older Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A 4-Year Experience From the REASONATE-2 Study. EHA 23 Proceedings. 2018. P. Abstract PF343.
35. Woyach JA et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 2018; 379 (26): 2517–28.
36. Nikitin E. Randomised Comparison Of FCR-Lite And ClbR (Chlorambucil Plus Rituximab) Regimens In Elderly Patients With Chronic Lymphocytic Leukemia. EHA 18 Proceedings. 2013. P. Abstract NS1147.
37. Foà R et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol 2014; 89 (5): 480–6.
38. Hillmen P et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. J Clin Oncol 2014; 32 (12): 1236–41.
39. Fischer K et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med 2019; 380 (23): 2225–36.
40. Jones JA et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 2018; 19 (1): 65–75.
41. Catovsky D, Else M, Richards S. Chlorambucil-still not bad: A reappraisal. Clin Lymphoma 2011; 11 (Suppl. 1): S2.
42. Hainsworth JD et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21 (9): 1746–51.
43. Michallet A-S et al. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group. Am J Hematol 2017; 92 (6): E105–E107.
44. Burger JA et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: A single-arm, phase 2 study. Lancet Oncol 2014; 15 (10): 1090–9.
45. Sorror ML et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008; 26 (30): 4912–20.
46. Dreger P et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: Long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010; 116 (14): 2438–47.
47. Stilgenbauer S et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 2016; 17 (6): 768–78.
48. Tam CS et al. Life After FCR: Outcomes of patients with chronic lymphocytic leukemia who progress after frontline treatment with Fludarabine, Cyclophosphamide and Rituximab. Blood 2014; 3059–64.
49. Fischer K et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: A Multicenter Phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011; 29 (26): 3559–66.
50. Byrd JC et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371 (3): 213–23.
51. Moreno C et al. Ibrutinib in previously treated chronic lymphocytic leukemia: updated efficacy and safety of the RESONATE study with up to four years of follow-up. EHA 22 Proceedings. 2017. P. Abstract S769.
52. Chanan-Khan A et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): A randomised, double-blind, phase 3 study. Lancet Oncol 2016; 17 (2): 200–11.
53. Hallek M et al. Three-year follow-up of patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving ibrutinib plus bendamustine and rituximab (BR) versus placebo plus BR: an update of the HELIOS study. Leuk Lymphoma 2017; 58: 192–4.
54. Seymour JF et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 2018; 378 (12): 1107–20.
55. Castro JE et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 2009; 23 (10): 1779–89.
56. Raanani P et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma 2009; 50 (5): 764–72.
57. Константинова Т.С., Клясова Г.А., Капланов К.Д. Лечение и профилактика инфекционных осложнений у пациентов с лимфопролиферативными заболеваниями. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 289–311.
[Konstantinova T.S., Kliasova G.A., Kaplanov K.D. Lechenie i profilaktika infektsionnykh oslozhnenii u patsientov s limfoproliferativnymi zabolevaniiami. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoy, V.G.Savchenko. 2018; p. 289–311 (in Russian).]
58. Rubin LG et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58 (3): 309–18.
59. Sinisalo M et al. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br J Haematol 2001; 114 (1): 107–10.
60. Абузарова Г.Р. и др. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И.Пирогова Минздрава России, 2016.
[Abuzarova G.R. et al. Obezbolivanie vzroslykh i detei pri okazanii meditsinskoi pomoshchi. Metodicheskie rekomendatsii. FGBOU VO RNIMU im. N.I.Pirogova Minzdrava Rossii, 2016 (in Russian).]
61. Абузарова Г.Р. Лечение болевого синдрома у онкологических больных. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 278–88.
[Abuzarova G.R. Lechenie bolevogo sindroma u onkologicheskikh bol'nykh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoy, V.G.Savchenko. 2018; p. 278–88 (in Russian).]
62. Paul KL. Rehabilitation and exercise considerations in hematologic malignancies. Am J Phys Med Rehabil 2011; 90 (5 Suppl. 1): S88–94.
63. Reda G et al. Secondary Malignancies in Chronic Lymphocytic Leukemia: A Single Centre Retrospective Analysis of 514 Cases. Blood 2015; 126 (23).
64. Beiggi S et al. Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study. Br J Cancer 2013; 109 (5): 1287–90.
65. Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (6): 649–55.
66. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968; 16 (5): 622–6.

________________________________________________

1. Packham G, Stevenson F. The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia. Semin Cancer Biol 2010; 20 (6): 391–9.
2. Vardi A et al. Immunogenetic studies of chronic lymphocytic leukemia: Revelations and speculations about ontogeny and clinical evolution. Cancer Res 2014; 74 (16): 4211–6.
3. Murray F et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: Implications for the role of antigen selection in leukemogenesis. Blood 2008; 111 (3): 1524–33.
4. Strati P, Shanafelt T.D. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: Diagnosis, natural history, and risk stratification. Blood. Am Soc Hematol 2015; 126 (4): 454–62.
5. Zhang S, Kipps TJ. The Pathogenesis of Chronic Lymphocytic Leukemia. Annu Rev Pathol Mech Dis 2014; 9 (1): 103–18.
6. Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 2013; 34 (12): 592–601.
7. Morton LM et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107 (1): 265–76.
8. Watson L, Wyld P, Catovsky D. Disease burden of chronic lymphocytic leukaemia within the European Union. Eur J Haematol 2008; 81 (4): 253–8.
9. Jemal A et al. Cancer statistics, 2007. CA. Cancer J Clin 2007; 57 (1): 43–66.
10. Dores GM et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: Overview of the descriptive epidemiology. Br J Haematol 2007; 139 (5): 809–19.
11. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Pod red. A.D.Kaprina, V.V.Starinskogo, G.V.Petrovoi. Moscow: MNIOI im. P.A. Gertsena – filial FGBU "NMITs radiologii" Minzdrava Rossii, 2018 (in Russian).
12. Hallek M et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018; 131 (25): 2745–60.
13. Armitage J.O. Staging Non-Hodgkin Lymphoma. CA. Cancer J Clin. Wiley 2005; 55 (6): 368–76.
14. An international prognostic index for patients with chronic lymphocytic leukaemia ­(CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 2016; 17 (6): 779–90.
15. Swerdlow SH et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016.
16. Nikitin E.A. et al. Khronicheskii limfoleikoz. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 179–200 (in Russian).
17. Morice WG et al. Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: Comparative analysis of flow cytometry and tissue biopsy in 252 patients. Mayo Clin Proc 2008; 83 (7): 776–85.
18. Rawstron AC et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008; 359 (6): 575–83.
19. Molica S, Giannarelli D, Montserrat E. Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis. Clin Lymphoma Myeloma Leuk 2019; 19 (7): 423–30.
20. Rossi D et al. Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naïve patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50 (4): 604–11.
21. Conte MJ et al. Use of positron emission tomography- computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma Informa Healthcare 2014; 55 (9): 2079–84.
22. Parikh SA, Kay NE, Shanafelt TD. How we treat Richter syndrome. Blood 2014; 123 (11): 1647–57.
23. Hallek M et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010; 376 (9747): 1164–74.
24. Fischer K et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial. Blood 2016; 127 (2): 208–15.
25. Fischer K et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012; 30 (26): 3209–16.
26. Eichhorst B et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2016; 17 (7): 928–42.
27. Shanafelt T, Wang V, Kay N. A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): a trial of the ECOG-ACRIN Cancer. ASH Annual Meeting. 2018. P. LBA-4.
28. Burger JA et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 2019; 133 (10): 1011–9.
29. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology. Chronic Lymphocytic Leukemia. Small Lymphocytic Lymphoma. 2019.
30. Assouline S et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia ­(SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematol 2016; 3 (3): e128–38.
31. Goede V et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370 (12): 1101–10.
32. Michallet AS et al. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: Primary analysis of the randomized, open-label mable study. Haematologica. Ferrata Storti Foundation 2018; 103 (4): 698–706.
33. Burger JA et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015; 373 (25): 2425–37.
34. Burger JA et al. Ibrutinib for First-Line Treatment of Older Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A 4-Year Experience From the REASONATE-2 Study. EHA 23 Proceedings. 2018. P. Abstract PF343.
35. Woyach JA et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 2018; 379 (26): 2517–28.
36. Nikitin E. Randomised Comparison Of FCR-Lite And ClbR (Chlorambucil Plus Rituximab) Regimens In Elderly Patients With Chronic Lymphocytic Leukemia. EHA 18 Proceedings. 2013. P. Abstract NS1147.
37. Foà R et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol 2014; 89 (5): 480–6.
38. Hillmen P et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. J Clin Oncol 2014; 32 (12): 1236–41.
39. Fischer K et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med 2019; 380 (23): 2225–36.
40. Jones JA et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 2018; 19 (1): 65–75.
41. Catovsky D, Else M, Richards S. Chlorambucil-still not bad: A reappraisal. Clin Lymphoma 2011; 11 (Suppl. 1): S2.
42. Hainsworth JD et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21 (9): 1746–51.
43. Michallet A-S et al. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group. Am J Hematol 2017; 92 (6): E105–E107.
44. Burger JA et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: A single-arm, phase 2 study. Lancet Oncol 2014; 15 (10): 1090–9.
45. Sorror ML et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008; 26 (30): 4912–20.
46. Dreger P et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: Long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010; 116 (14): 2438–47.
47. Stilgenbauer S et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 2016; 17 (6): 768–78.
48. Tam CS et al. Life After FCR: Outcomes of patients with chronic lymphocytic leukemia who progress after frontline treatment with Fludarabine, Cyclophosphamide and Rituximab. Blood 2014; 3059–64.
49. Fischer K et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: A Multicenter Phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011; 29 (26): 3559–66.
50. Byrd JC et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371 (3): 213–23.
51. Moreno C et al. Ibrutinib in previously treated chronic lymphocytic leukemia: updated efficacy and safety of the RESONATE study with up to four years of follow-up. EHA 22 Proceedings. 2017. P. Abstract S769.
52. Chanan-Khan A et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): A randomised, double-blind, phase 3 study. Lancet Oncol 2016; 17 (2): 200–11.
53. Hallek M et al. Three-year follow-up of patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving ibrutinib plus bendamustine and rituximab (BR) versus placebo plus BR: an update of the HELIOS study. Leuk Lymphoma 2017; 58: 192–4.
54. Seymour JF et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 2018; 378 (12): 1107–20.
55. Castro JE et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 2009; 23 (10): 1779–89.
56. Raanani P et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma 2009; 50 (5): 764–72.
57. Konstantinova T.S., Kliasova G.A., Kaplanov K.D. Lechenie i profilaktika infektsionnykh oslozhnenii u patsientov s limfoproliferativnymi zabolevaniiami. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoy, V.G.Savchenko. 2018; p. 289–311 (in Russian).
58. Rubin LG et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58 (3): 309–18.
59. Sinisalo M et al. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br J Haematol 2001; 114 (1): 107–10.
60. Abuzarova G.R. et al. Obezbolivanie vzroslykh i detei pri okazanii meditsinskoi pomoshchi. Metodicheskie rekomendatsii. FGBOU VO RNIMU im. N.I.Pirogova Minzdrava Rossii, 2016 (in Russian).
61. Abuzarova G.R. Lechenie bolevogo sindroma u onkologicheskikh bol'nykh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoy, V.G.Savchenko. 2018; p. 278–88 (in Russian).
62. Paul KL. Rehabilitation and exercise considerations in hematologic malignancies. Am J Phys Med Rehabil 2011; 90 (5 Suppl. 1): S88–94.
63. Reda G et al. Secondary Malignancies in Chronic Lymphocytic Leukemia: A Single Centre Retrospective Analysis of 514 Cases. Blood 2015; 126 (23).
64. Beiggi S et al. Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study. Br J Cancer 2013; 109 (5): 1287–90.
65. Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (6): 649–55.
66. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968; 16 (5): 622–6.

Е.А. Никитин1, Т.Е. Бялик2, А.Ю. Зарицкий3, Л. Исебер4, К.Д. Капланов5,6, Т.Н. Лопаткина2, С.А. Луговская7, О.В. Мухортова8, Е.А. Османов2,9, И.В. Поддубная6, О.С. Самойлова10, Е.А. Стадник3,11, Н.А. Фалалеева12, В.В. Байков11, 
А.М. Ковригина13,14, А.А. Невольских12, С.А. Иванов12, Ж.В. Хайлова12, Т.Г. Геворкян9

1 ГБУЗ «Городская клиническая больница им. С.П. Боткина» Департамента здравоохранения г. Москвы, Москва, Россия;
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
3 ФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова» Минздрава России, Санкт-Петербург, Россия;
4 Онкологический центр Тулузы, Тулуза, Франция;
5 ГБУЗ «Волгоградский областной клинический онкологический диспансер», Волгоград, Россия;
6 ФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава России, Волгоград, Россия;
7 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия;
8 ФГБУ «Национальный медицинский исследовательский центр сердечно-сосудистой хирургии им. А.Н. Бакулева» 
Минздрава России, Москва, Россия;
9 ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России, Москва, Россия;
10 ГБУЗ НО «Нижегородская областная клиническая больница им. Н.А. Семашко», Нижний Новгород, Россия;
11 ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» 
Минздрава России, Санкт-Петербург, Россия;
12 Медицинский радиологический научный центр им. А.Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России, Москва, Россия;
13 Академия постдипломного образования ФМБА России, Москва, Россия;
14 ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России, Москва, Россия

________________________________________________

Evgenii A. Nikitin1, Tatiana E. Bialik2, Andrei Iu. Zaritskii3, Loik Iseber4, Kamil D. Kaplanov5,6, Tatiana N. Lopatkina2, Svetlana A. Lugovskaia7, Olga V. Mukhortova8, Evgenii A. Osmanov2,9, Irina V. Poddubnaya6, Olga S. Samoilova10, Elena A. Stadnik3,11, Natalia A. Falaleeva12, Vadim V. Baikov11, Alla M. Kovrigina13,14, Aleksei A. Nevol'skikh12, Sergei A. Ivanov12, Zhanna V. Khailova12, Tigran G. Gevorkian9

1 Botkin City Clinical Hospital, Moscow, Russia;
2 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
3 Almazov National Medical Research Centre, Saint Petersburg, Russia;
4 Toulouse Cancer Center, Toulouse, France;
5 Volgograd Regional Clinical Oncological Dispensary, Volgograd, Russia;
6 Volgograd State Medical University, Volgograd, Russia;
7 Russian Medical Academy of Continuous Professional Education, Moscow, Russia;
8 Bakulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russia;
9 Blokhin National Medical Research Center of Oncology, Moscow, Russia;
10 Semashko Nizhny Novgorod Regional Clinical Hospital, Nizhny Novgorod, Russia;
11 Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia;
12 Tsyba Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology, Moscow, Russia;
13 Academy of Postgraduate Education, Moscow, Russia;
14 National Research Center for Hematology, Moscow, Russia